About the Technology

Magnetic fluid hyperthermia (MFH) is an electromagnetic thermal treatment that is still experimental in the USA, but it is approved in Europe. However, there is a certain exclusion criteria for patients with metallic implants below their neck because the implants would heat under the treatment. Therefore, iHnnova LLC is working on a way to deliver MFH treatment to cancer patients with metallic implants to extend MFH accessibility.  

We are proposing the use of our patented (U.S. Patent 10,736,684) handheld laparoscopic induction heater (LIH) and transrectal induction heater (TRIH) for treatment of pancreatic cancer (PanC) and prostate cancer (PCa), respectively. Our solution is based on MFH, a significant technically disruptive method that has been considered to have potential in the treatment of cancer. MFH takes advantage of induction heating in delivering heat to a target object. This thermal therapy consists of applying a high intensity, high frequency magnetic field to magnetic nanoparticles with the purpose of damaging cancerous tissue. The damage mainly depends on the characteristics of the magnetic field, the nanoparticle platform used, treatment time and temperature reached. For MFH, the desired target temperature in the tumor is about 41–43°C.